<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985463</url>
  </required_header>
  <id_info>
    <org_study_id>2014-402M-MA-§ 23b MPG</org_study_id>
    <nct_id>NCT02985463</nct_id>
  </id_info>
  <brief_title>Left Atrial Appendage Occlusion and Biomarker Evaluation</brief_title>
  <acronym>LABEL</acronym>
  <official_title>Left Atrial Appendage Occlusion and Biomarker Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Left Atrial Appendage Occlusion and Biomarker Evaluation&quot; (LABEL) is a single-center,
      prospective and observational study evaluating changes of the expression of biomarkers in
      eligible patients before and after percutaneous implantation of a left atrial appendage (LAA)
      occlusion device at mid-term follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the changes of different types of biomarkers before and after
      successful percutaneous implantation of an LAA occlusion device.

      Biomarker evaluation will focus on blood derived biomarkers including neurohormones,
      proteins, cytokines, microRNAs and metabolomics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker levels before successful LAA occlusion device implantation</measure>
    <time_frame>24 hours before intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker levels after successful LAA occlusion device implantation</measure>
    <time_frame>mid-term follow up at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of biomarker expression before and after device implantation over mid-term follow-up, depending of complete, incomplete occlusion, imaging data (transesophageal echocardiography, computed tomography)</measure>
    <time_frame>mid-term follow up at 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Bleeding</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two peripheral blood withdraws in EDTA, citrate, ammonium heparin, serum tubes 24 hours
      before and at mid-term follow up at 6 months after successful LAA occlusion device
      implantation.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from non valvular atrial fibrillation with a contraindication for oral
        anticoagulation (i.e. bleeding) being eligible of percutaneous implantation of LAA
        occlusion devices.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non valvular atrial fibrillation, that makes anticoagulation to prevent embolic stroke
             from the LAA

          -  contraindication for the therapy with oral anticoagulants:

          -  refusal to take oral anticoagulation

          -  HasBled-score more than 3

          -  prior bleedings under oral anticoagulation

        Exclusion Criteria:

          -  under 18 years

          -  severely reduced left atrial function

          -  mechanical heart valve

          -  pulmonary embolism

          -  deep vein thrombosis

          -  myocardial infarction within the last 3 months

          -  electrical cardioversion within 30 days after potential occluder implantation

          -  atrial septum defect or interventional/surgical occlusion of ASD

          -  status after heart transplant

          -  symptomatic carotid artery stenosis

          -  transient ischemic attack (TIA) or stroke within last 30 days

          -  intracerebral bleeding within the last 2 months

          -  acute infection

          -  existing or planned pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibrahim Akin, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ibrahim Akin, Prof. Dr.</last_name>
    <phone>0049 621 383 5229</phone>
    <email>ibrahim.akin@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Behnes, Dr. med.</last_name>
    <phone>0049 621 383 6239</phone>
    <email>michael.behnes@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Akin, MD</last_name>
      <phone>0049 621 383 5229</phone>
      <email>ibrahim.akin@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Behnes M, Akin I, Sartorius B, Fastner C, El-Battrawy I, Borggrefe M, Haubenreisser H, Meyer M, Schoenberg SO, Henzler T. --LAA Occluder View for post-implantation Evaluation (LOVE)--standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography. BMC Med Imaging. 2016 Mar 24;16:25. doi: 10.1186/s12880-016-0127-y.</citation>
    <PMID>27009279</PMID>
  </reference>
  <results_reference>
    <citation>Fastner C, Behnes M, Sartorius B, Yildiz M, Mashayekhi K, El-Battrawy I, Lehmann R, Baumann S, Becher T, Borggrefe M, Akin I. Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovasc Disord. 2016 Jan 28;16:25. doi: 10.1186/s12872-016-0200-z.</citation>
    <PMID>26822890</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2016</study_first_submitted>
  <study_first_submitted_qc>December 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Michael Behnes</investigator_full_name>
    <investigator_title>Dr. med</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

